Skip to main content

Advertisement

Table 3 Adverse events with tofacitinib at week 12 and withdrawal from trials

From: Efficacy and safety of tofacitinib in the treatment of rheumatoid arthritis: a systematic review and meta-analysis

  5 mg bid 10 mg bid
Adverse events No. of studies Sample size (tofacitinib, placebo) Risk ratio [95% CI] No. of studies Sample size (tofacitinib, placebo) Risk ratio [95% CI]
Infection       
Upper respiratory tract infection 4 901, 522 1.12 [0.61, 2.05] 4 896, 522 0.77 [0.40, 1.49]
Urinary tract infection 4 901, 522 1.22 [0.58, 2.57] 4 901, 522 1.01 [0.45, 2.27]
Bronchitis 4 901, 522 0.80 [0.25, 2.56] 4 896, 522 1.01 [0.34, 2.96]
Nasopharyngitis 5 928, 550 1.57 [0.51, 4.83] 5 922,550 1.67 [0.82, 3.39]
Influenza 3 768, 390 0.37 [0.08, 1.64] 3 762, 390 1.25 [0.25, 6.20]
Pharyngitis 2 231, 136 0.01 [−0.01, 0.03] 2 227, 136 0.03 [−0.09, 0.14]
Immune system       
Neutropeniaa 4 826, 482 1.41 [0.55, 3.61] 4 830, 482 1.73 [0.68, 4.38]
Rash 3 552, 296 0.32 [0.04, 2.61] 3 543, 296 2.51 [0.63, 9.93]
Withdrawal No. of studies Tofacitinib N (%) Placebo N (%)    Risk ratio [95% CI]
All causes 5 158 (12.31%) 59 (16.71%)    0.60 [0.45, 0.78]
Adverse events 5 50 (3.89%) 8 (2.27%)    1.43 [0.68, 3.03]
Lack of efficacy 5 16 (1.25%) 20 (5.67%)    0.18 [0.09, 0.35]
  1. bid twice daily; CI confidence interval; amild, 1500–1999 cells/mm3.